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Highlights:  
• Lower than previously reported infection rates following DBS for movement 
disorders in children were identified and no increased susceptibility for patients 
younger than 7 years.  
• We report relatively high incidence of technical problems with electrodes and 
extensions and in particular recharging. 
• Presentation of heterogeneous phenotypes requires an experienced team to 
manage and prevent complications.  
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The paper confirms that DBS in young children is safe and can be offered.  
 
 
Abstract: 
Deep brain stimulation (DBS) has been increasingly used for primary and secondary 
movement disorders in children and young people. Reports of hardware related 
complications have been sparse for this population and from small cohorts of patients.  
We report DBS complications from a single large DBS centre with 10 year experience. 
Data was collected as a prospective audit and additionally from a questionnaire on 
recharging of the stimulators. 129 patients with a minimum 6 months follow up were 
identified, mean age10.8 y (range 3.0 – 18.75), mean follow up 3.3y (range 0.5 – 10.3), 
weight 10.4-94.2kg, 126 new implants (92 Activa RC) and 69 revisions for reasons other 
than infection. 26 patients were 7y or younger. Surgical site infections (SSI) rates were 
10.3% for new implants and revisions, lower 8.6% for new Activa RC and even lower, 
4.7%, for new Activa RC in patients under 7y (1/21). SSI occurred within first 6 months 
and necessitated total system removal in 86% of those infected. Electrode/extension 
problems were recorded in 18.4% of patients, fracture in 4.6% malfunction in 7.7%, 
short extension3.8% and electrode migration in 2.3%. Other complications involved 
clinically silent intracranial bleed in 1 patient, skin erosions (2.3%), unexpected 
switching off in 18.7% of Soletra/Kinetra and 3.4% of Activa RC, transient seroma at 
IPG site in postoperative period (8%). Of the 48 returned recharging questionnaires, 
38% of families required recharger replacement and 23% experienced frequent 
problems maintaining connection during recharging. However, 83% of responders 
considered recharging not at all or only a little care burden. 
We identified lower than previously reported DBS infection rates particularly for patients 
under 7 years, but relatively high incidence of technical problems with electrodes, 
extensions and in particular recharging. This has to be considered when offering DBS 
for children with movement disorders.   
    
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
Introduction: 
 
Dystonia in childhood is most frequently of a secondary aetiology, is unlikely to remit 
spontaneously 1 2 and negatively affects a child’s life including activity and participation3. 
Expression of dystonia on the background of a maturing central nervous system 
potentially leads to alteration of response to pharmacological agents4 5 . Multiple 
medications have been used in childhood dystonia without robust evidence and 
resulting in side effects in two thirds of patients6 . 
 
Deep Brain Stimulation has been increasingly used in the management of childhood 
dystonias. Favourable responses to DBS in primary dystonias have been well 
documented 7 8 9 10 11 12 and there is growing evidence supporting its use in secondary 
dystonias, however with more modest effects13 14 15 .  
Complications of DBS in paediatric populations have been sparsely reported in small 
cohorts of patients. We aim to report complications and discuss challenges of DBS for 
children from a single large paediatric centre with 10 year experience.  
 
Methods: 
 
Surgery: 
All DBS surgeries were performed under general anaesthesia as a one-stage 
procedure. In the first three years single channel Soletra and double channel Kinetra 
stimulators were implanted (Medtronic). Once a rechargeable Activa RC stimulator 
(Medtronic) became available in December 2008 it has been offered preferentially. A 
Leksell frame was used in all cases, with finger tightening of screws in the very young 
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patients. DBS electrodes were implanted bilaterally through frontal incisions and burr 
holes into posteromedial globus pallidus interna (GPI) in the majority of patients. Two 
patients with hemidystonia had unilateral implants (first - unilateral GPI and thalamus, 
second – unilateral GPI). Three patients had electrodes implanted in subthalamic 
nucleus (STN) bilaterally due to severe damage of globus pallidus, we reported 
previously early outcome of STN DBS in the first of these patients16. There were two 
patients with two pairs of electrodes in GPIs, one with additional pair implanted at 
revision and another with four electrodes implanted at initial procedure.  All new DBS 
patients underwent direct anatomical targeting using pre-operative high-resolution 
proton density and T1 weighted volume stereotactic brain MRI scans. Medtronic 
Framelink software was used to calculate the coordinates of the target. Post operative 
stereotactic CT scan was performed in all patients to confirm electrode placement. Intra-
operative impedance or microelectrode17  recordings were also used to improve 
localisation of the target. Accuracy of the electrodes placement has been validated 
retrospectively on the fused in frame preoperative MRI and postoperative CT 18. All 
electrodes used were Medtronic 3389. 
 
Patients with de novo implants received a 7-day prophylactic course of intravenous 
antibiotic (cefuroxime unless specific indications for a different antibiotic) following new 
implants. For battery replacement procedures 24-48 hours intravenous antibiotic 
prophylaxis was used initially, and from June 2010 the protocol was unified to 7-day 
course for new implants and all revision procedures.  
 
When changing neurostimulators from Soletra and Kinetra to Activa RC an adaptor was 
used to enable connection of the existing extensions to Activa RC. The adaptor was 
positioned behind the neurostimulator to avoid interference with recharging19. 
 
For Activa RC stimulators all families (children and caregivers where relevant) received 
an information session on recharging the stimulator prior to surgery and individual 
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practical training during the postoperative 7 days admission until they felt confident with 
the stimulator maintenance. Families were advised to recharge stimulator initially daily 
to ensure the process became a routine care and to maintain high battery charge – 75 
to 100%. 
 
Data collection and analysis: 
Patients undergoing DBS surgery in our paediatric centre during 10 years between May 
2005 and October 2015 were prospectively monitored for surgery related complications. 
Cases with a minimum of 6 months follow up were entered for further analysis.  
 
Additionally a questionnaire on recharging technique, frequency, duration and any 
related difficulties was applied to the patients with rechargeable stimulators on the with 
a minimum 6 months follow up.  
Patients’/caregivers’ responses were recorded during clinic appointments or over the 
telephone or filled questionnaires were returned via email. 
 
Simple percentage analysis was used.  
 
 
Results: 
 
Patients and procedures – Figure 1: 
138 paediatric patients with DBS were under our care between June 2005 and October 
2015. 129 patients had a follow up of minimum 6 months, of these 126 had de novo 
implants in our centre and 3 patients had original implants elsewhere. There were 69 
revision procedures not related to infection, mainly battery changes. 
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Mean age at the DBS implant was 10.8 y (range 3.0 – 18.75) and 26 patients were 
younger than 7years. Mean follow up was 3.3y (range 0.5 – 10.3). Patients’ weight 
ranged between 10.4 and 94.2kg.  
 
Within new implants 32 received Soletra and Kinetra stimulators, 92 Activa RC and 2 
patients had Activa PC. 22 patients had Soletra and Kinetra stimulators replaced with 
Activa RC over the course of the study period. When the rechargeable stimulator 
became available, although we strongly encouraged this type of implant, few patients 
had a non-rechargeable stimulators implanted due to their/family preference. 
 
29 patients were transitioned to the adult services, 1 patient was lost to follow up. 10 
patients died due to underlying natural history of the diagnosis at time points unrelated 
to surgery (Table 1). The exception was a patient (case 4 Table 1) with Aicardi-
Goutieres Syndrome type 6 who died within 24 hours post DBS electrode revision after 
an initial normal post-operative recovery – post mortem examination failed to identify 
cause of death and specifically there was no evidence of an intracranial bleed.  
 
Surgical site infections: 
Surgical site infection rate was 8.6% for new Activa RC implants. Overall surgical site 
infection rate was 10.3% for all new implants and 10.1% for revisions. A lower rate 
(7.6%) was recorded for patients under 7y at the time of implant (2/26) and even lower 
rate of 4.7% in a group of patients under 7y with new Activa RC implants (1/21). 
All surgical site infections occurred within the first 6 months after surgery. Treatment 
with prolonged courses of antibiotics was unsuccessful in 86% of patients with surgical 
site infections following new implants and revisions, necessitating eventually total 
removal of the DBS system.   
 
Other hardware related complications: 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
A clinically insignificant small intracranial bleed was detected on postoperative CT at the 
site of one electrode in one patient (0.8%) and a self - resolving small CSF collection on 
the scalp in one patient. Overall, 8% of patients developed self - resolving seromas in 
the postoperative period, primarily at the battery site.  
 
Three patients (2.3%) developed skin erosions eventually leading to full system 
explantation in all. One patient developed an unusual granuloma 4 years after the DBS 
implant and another developed late infection following trauma and haematoma at the 
stimulator site two years after the surgery.  
 
18.4% of patients experienced problems with electrode leads and extensions:  
short/tight extension was observed in 3.8%, electrode migration in 2.3%, 
electrode/extension fracture in 4.6% and electrode/extension malfunction in 7.7%. 
Electrode/extension malfunction was defined as high impedance on at least one contact 
in monopolar settings (>4000 Ω for Kinetra and Activa; > 2000 Ω for Soletra) or 
significant fluctuations of therapy current (minimum 50% fluctuations on different 
measurements of the same therapy settings) including very low current drain.  
 
Two patients (1.5%) remain with the DBS switched off due to perceived intolerable side 
effects of stimulation, low mood (abullia) relative to previous  smiling, likely partially 
dyskinetic, and ebullience in one and increased rigidity in another.  
 
The IPG was unexpectedly (not related to battery depletion) switched off in 18.7% of 
patients with Soletra and Kinetra and in 3.4% of patients with Activa RC.  
 
Status dystonicus following disruption of DBS was observed in 6 patients (4.6%) after 
IPG was switched off unexpectedly in 2 cases, electrode fracture in 1 and system 
removal in 3.  
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Complications related to recharging:  
Shielded battery syndrome17 preventing recharging of the neurostimulator due to 
anterior position of adaptor or rotational flipping over of Activa RC occurred in two cases 
following replacement of Kinetra with an Activa RC stimulator. With the adaptation of 
surgical technique no more such cases were observed. Two overweight patients (1.7%) 
required Activa RC repositioning due to difficulty recharging.  
 
Questionnaire on recharging: 
We obtained 48 completed recharging questionnaires (Fig 2). Parents and carers were 
responsible for recharging of the stimulators in 69 % and patients themselves in 29%. 
The stimulators were recharged every day or every 2-3 days in the majority of cases 
(79%) during quiet activities (69%) and the recharging session was shorter than 1 hour 
in 73%.  
 
Various methods were used to maintain connection between the battery and recharger 
with the recharger held by hand in most (48%) and original belt or harness used only in 
14%.  
77% of families have never or only sometimes experienced difficulty maintaining 
connection, however 14% had difficulty most or all the time.  
 
The recharger had to be replaced due to malfunction in 38% of cases, and twice in 6%. 
The battery was reported to be fully discharged (battery flat) at least once in 23% 
including 13% more than once.  
83% of responders considered recharging of DBS stimulator as ‘not at all’ or ‘only a 
little’ of a care burden.  
 
 
Discussion: 
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Surgical site infections and erosions: 
 
We identified 8.6% infection rate for new Activa RC implants in comparison to a higher 
10.3% for all new implants in the whole cohort and 10.1% for revision procedures. This 
is in line with reports of 1.2-15% from adult cohorts20 21 22 23. Higher infection rates 9.3 – 
21% have been reported in paediatric cohorts or case series 24 25 26 27 28 29 30. Although 
Olaya et al 31  reported no complications in case series of 9 patients, Air et al 27 reported 
a 57% infection rate in patients younger than 10y. Keen et al 26 suggested that young 
children may have increased infection risk after reporting a 40% rate in a small group of 
5 patients aged 8-17y.  
This is in contrast to our finding of only 7.6% in our patients under 7 y and even lower 
(4.7%) if they had new Activa RC implant. We postulate that lower rate of infections in 
Activa RC new implants group can be related to its smaller size and favourable shape 
resulting in easier accommodation of an implant, but a growing experience of the centre 
in relation to surgery and perioperative care may also be an important factor.  
 
Staphylococcus aureus was the most common infection-site culture and despite 
different antibiotic regimens and partial system removal in some cases, 86% of infected 
systems were eventually totally removed. A majority (58%) of patients had very 
localised symptoms, comprising delayed wound healing with purulent discharge without 
fever or raised inflammatory markers. However, one patient with severe cerebral palsy 
and malnutrition developed sepsis necessitating intensive care support and urgent 
system removal. Another child with severe PKAN (PANK-2 positive) disease had DBS 
implanted directly from PICU for status dystonicus precipitated by unsuspected acute 
Hepatitis A which was diagnosed 3 weeks after DBS implant with the onset of jaundice 
and acutely deranged liver function tests, complicated by nephrotic syndrome. This 
immunocompromise resulted in a brain abscess along left DBS lead requiring DBS 
removal with minimal residual scarring.  
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Another seven patients developed cellulitis with significantly elevated inflammatory 
markers.  
None of these had permanent sequelae due to DBS infection.  
 
Three patients presented with skin erosion (two over the IPG positioned in the upper 
chest, one on the scalp) at 11, 42 and 22 months after surgery respectively without 
signs of infection and negative or inconclusive microbiology results. All of these cases 
were severely malnourished with body-weights below the 0.4th centile which we believe 
contributed to this complication. Our practice has changed since and the stimulators are 
implanted in the abdomen particularly in patients with low weight.  
 
Electrode leads and extension problems   
 
Complications related to electrodes and extensions were not uncommon in our cohort 
(18.4%). This is higher that reported in the literature 20 21 22 23 28  although 14% lead 
fractures were recorded in a series of 14 patients 29. In our series, particularly frequent 
were electrode/extension fractures and malfunction (12.3%). In one case an electrode 
fracture presented as deterioration of dystonia without typical very high impedances. 
Nevertheless, we recommend that the therapy and electrode impedances should be 
measured during every programming session and particularly when deterioration of 
symptom control is noted. An X-ray should be performed in cases of high impedance or 
significant fluctuations of impedance and current or unexplained deterioration of 
dystonia to exclude an electrode or extension fracture. 
 
 
Recharging 
 
Rechargeable Activa RC stimulators have been almost exclusively implanted in our 
centre since December 2008 (Fig 1) due to its small size, important for our population of 
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patients, and to reduce the frequency of battery replacement  32. Increased risk of 
implant infection related to higher number of surgical revisions, including IPG 
replacement, has been reported 33 34. 
Economic savings can be expected from implantation of rechargeable vs non-
rechargeable IPG 35  alongside with a high patient satisfaction from rechargeable 
stimulators 36 37.  
Indeed, the majority of patients/carers in our cohort (84%) indicated that recharging was 
‘not at all’ or ‘only a little’ care burden. However, a third of families required a recharger 
replacement and a fifth had frequent difficulty maintaining connection between the 
recharger and the battery. As previously reported 37 the majority of carers did not use 
the harness or belt supplied by the manufacturer as they were not suitable either due to 
patient small size or severe dystonic/dyskinetic movements.  
Unexpected IPG switching off, not related to battery failure, occurred in 18.7% of 
children with Soletra and Kinetra neurostimulators falling to 3.4% in patients with Activa 
RC implants. This is despite of the fact that a patient control device was offered 
routinely to all patients with rechargeable stimulators, thus increasing possibility of 
neurostimulator accidental switching off by patient/carers while patient control device 
was not supplied for patients with Soletra and Kinetra. 
Interestingly 23% of rechargeable stimulators were reported by questionnaire 
responders (11/48) to be fully discharged at least once. This warrants closer inspection 
of device usage history at each review point and active reminding about the necessity of 
recharging.  Nonetheless we have not experienced Activa RC permanent battery failure 
to date.  
 
 
Deterioration of dystonia in the post-operative period 
Dyskinetic storms can emerge in patients with Parkinson Disease and STN DBS 
postoperatively 38 39. Similarly we observed in some cases significant deterioration of 
dystonia or dyskinesia in the postoperative period requiring transient escalation of 
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medical treatment. This predominantly occurred in younger children with a more severe 
background dystonia and may have been related to many factors such as stress of 
surgery and hospital admission, fear, pain, difficulty communicating needs, constipation, 
vomiting and intolerance of DBS settings. This has not been included in the data 
collection therefore it is not possible to give quantitative, but only qualitative description. 
We have introduced routine morphine infusions (Nurse Controlled Analgesia) for a 
minimum of the first 12 hours postoperatively and proactively managed pain, 
constipation, feeding, vomiting with improved patient comfort and experience. 
Nonetheless change of DBS settings (mainly reduction of voltage and/or pulse width) 
and escalation of medication for dystonia was still necessary in some.  
 
 
Status dystonicus after disruption of DBS 
 
Sudden discontinuation of DBS may result in return of dystonia 39 40 41. This may occur 
as a consequence of the system switching off unexpectedly, battery failure, 
electrode/extension fracture or malfunction. Symptoms can return gradually or lead to 
severe deterioration including status dystonicus in short order. In our cohort 4.6 % of 
patients developed difficult-to-treat or refractory status dystonicus after disruption of 
stimulation and many had milder, more gradual deterioration.  Re-institution of DBS 
where possible led to resolution of symptoms or significantly helped in the management.  
Our observation is that severe status dystonicus with active DBS is very rare in patients 
other than suffering from PKAN and even in these cases treatment is much more 
difficult when DBS is discontinued. However, we have not formally analysed our cohort 
to ascertain the incidence of status dystonicus or severe exacerbation of dystonia when 
receiving active stimulation. 
 
 
Limitations  
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We reported hardware related complications from a large paediatric cohort, however 
this cohort is not as large as in some adult studies.  
DBS for children with dystonia was a relatively new experience at the beginning of data 
collection, with limited reports on complications available and emergence of new 
complications with time. This might have resulted in delayed recognition of some 
problems e.g. electrode malfunction when impedances were high on two vs more 
contacts.  Our patients inevitably move on to the adult services, which are more local to 
them as opposed to our service accepting referrals often from a great distance. It has 
an impact on the length of follow up e.g. a patient receiving DBS at 16 years of age will 
likely leave our service after 2 years.  
 
 
Conclusions: 
DBS in children may be unduly delayed because of concerns of a greater complication 
risks in young children. We show here that device infection remains the most significant 
adverse event although with much lower rates than in previously reported small sample 
case-series of children under 10 years. In particular we do not show increased 
susceptibility in young patients below 7 years of age. This implies that medical and 
surgical experience is important in teams delivering DBS to children. This information 
also supports a practice of safe early DBS in an attempt to mitigate or forestall 
inevitable co-morbidities such as functional musculoskeletal deformities 42 and adverse 
drug reactions 6 but perhaps even more importantly to capitalise on the activity –
dependent plasticity of the developing brain as discussed by Ismail, Fatemi and 
Johnston (EJPN Special Edition on Neuromodulation).  
DBS in children and young people, although helpful in the management of movement 
disorders, can be associated with frequent other hardware related complications. 
Adverse events related to electrode and extension malfunction are common and most 
often require surgical intervention. Although rechargeable stimulator is well - accepted 
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by most of the patients, the maintenance can be challenging particularly in young/small-
sized patients with severe involuntary movements and those with learning or 
developmental delay. A small, skull-mounted neurostimulator, avoiding wires crossing 
the neck into the chest or abdomen, and a longer lifespan or better suited recharging 
equipment would be a very welcome development.  
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Diagnosis Age at 
surgery 
in years 
Age of death in 
years 
DBS 
in 
situ 
Y/N 
comments 
1 PKAN* 4.25   8.8 
4 years after 
DBS removed 
N DBS implanted for status 
dystonicus requiring PICU. 
Acute Hepatitis A 
diagnosed 3 weeks later 
complicated by nephrotic 
syndrome. This 
immunocompromise 
resulted in brain abscess 
along left lead requiring 
DBS removal. No residual 
scarring. DBS re-implant 
declined by the family.  
Patient died while on 
holiday abroad due to 
unexplained 
haematemesis.  
2 PKAN* 7.9 12.6 Y Patient died in sleep at 
the end stage of disease.  
3 PKAN* 10.5 18 Y Patient died at the end 
stage of disease.  
4 Aicardi-Goutieres 
Syndrome 
6.6 10.5 Y Died within 24 hours after 
DBS electrode 
replacement, respiratory 
arrest, examination post 
mortem did not reveal the 
cause of death. 
5 Aicardi-Goutieres 
Syndrome 
3.3 9.2 
1 year after DBS 
removed 
N DBS removed due to 
infection following 
revision. 
6 Glutaric Aciduria 
type 1 
10.6 14.3 Y DBS inserted as a 
palliative measure but 
non-rechargeable battery 
not replaced, therefore 
stimulation ceased. 
Patient died with full 
palliative care support.  
7 PKAN* 16.4 18.5 N DBS implanted in 
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Table 1:        Patients deaths 
11 months after 
DBS removed 
advanced stage of disease 
in patient with 
tracheostomy colonised 
with Pseudomonas and 
MRSA. System removed 
due to infection. Patient 
died with full palliative 
care support. 
8 PKAN* 14.3 18.1 Y Patient found dead at the 
end stage of disease in 
the residential care centre 
with neck hyperextended. 
Further details unknown.  
9 PKAN* 10.2 11.2 Y Patient died due to 
aspiration pneumonia. 
10 Undiagnosed 
secondary 
dystonia/chorea 
12.5 15.2 
5 months after 
DBS  
removed 
N DBS removed due to 
infection following new 
implant. Dystonia 
deteriorated significantly 
requiring dramatic 
escalation of medications.  
 
*Pantothenate Kinase Associated Neurodegeneration 
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Table 2: DBS in children - hardware related complications 
 
 
 
 
 
Complication 
 
 
% of patients 
Surgical site infections  new implants (all) 10.3 
                                         new implants Activa RC   8.6 
                                         new implants under 7 y    7.6 
                                         new implants under 7y Activa RC   4.7 
 Surgical site infections - revisions  10.1 
Skin erosion   2.3 
Seroma   8 
Intracranial bleeding (asymptomatic)    0.8 
CSF collection on a scalp   0.8 
Electrode/extension  problems (all) 18.4 
                                      fracture   4.6 
                                      malfunction   7.7 
                                      migration   2.3 
                                      Short/tight extension    3.8 
Battery switched off unexpectedly Soletra/Kinetra 18.7 
Battery switched off unexpectedly Activa RC   3.4 
Status dystonicus following sudden cessation of DBS   4.6 
Recharging of stimulator:  
Shielded battery syndrome (Kinetra replaced with Activa RC) 14 (2 of 14 
patients) 
Battery repositioned for difficulty recharging in overweight 
patients 
  2 
Significant difficulty maintaining connection during recharging 23 
Recharger replaced at least once 38 
Battery flat at least once 23 
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Figure 1: 
a)   Patients and  implanted new stimulators 
b)   Patients and follow up  
a) 
 
 
 
b) 
 
 
138
patients with DBS
129
follow up
> 6 months
126
new implants in our 
centre
32
Soletra and Kinetra 
stimulators
2
Activa PC
92 
Activa RC
3
new implants in 
other centres9
follow up 
< 6 months
129
patients with 
FU >6 months
10 patients 
died
1 patient lost to 
follow up
29 patients 
transitioned 
89 
patients under 
active follow up
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Figure 2:  
Results of survey on recharging of the DBS battery (48 patients) 
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